Drug intelligence / Profile preview

Can-SEEK

Development stage: Preclinical
Lead developer: POINT Biopharma
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Can-SEEK is a preclinical-stage radiotheranostic program developed by Bach Biosciences in collaboration with Point Biopharma. The platform consists of lead candidates designed to be activated by fibroblast activation protein (FAP), an enzyme highly expressed in the tumor microenvironment. Once activated, these radiopharmaceuticals target either prostate-specific membrane antigen (PSMA) or the folate receptor to deliver therapeutic or diagnostic radioactive isotopes directly to solid tumors. This dual-targeting or masked approach is intended to improve the precision of radioligand therapy by ensuring activation occurs primarily within the cancerous tissue.

Other names: Can-SEEK lead candidates

Targets

FOLR1 (FRα)

Beyond the preview

Go deeper on Can-SEEK.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Can-SEEK.

Explore the full profile